Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Publication date 04/04/2018 10:26 - Writing date 04/04/2018 10:25 - Equity data - Reco: Neutral - Target: € 15 - Equity Analyst : Alfred Glaser - [email protected] - +33-1 44 51 88 93 - ESG Analyst : Valentin Pernet - Corporate governance: Strong opportunity (1) - / - / - - - - - - - - - - - - - - - - - - - - Following the full-year 2017 earnings report and given the bonds issued last year, we have updated our recommendations on the three Rexel bonds....
A la suite de la publication des résultats annuels 2017 et compte tenu des émissions réalisées l’an dernier, nous avons rédigé un update de nos recommandations sur les trois souches obligataires Rexel. - >L’exercice 2017 a été marqué par un retour à la croissance et par une diminution du leverage. - Le chiffre d’affaires annuel est ressorti à 13 310 m EUR en 2017, en progression de 1.1% et de 3.5% en données comparables et à nombre de jours constants pour un Ebita ajusté de...
BOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL) ("PAREXEL" or the "Company"), a leading global biopharmaceutical services company, announced that Pamplona Capital Management, LLP (“Pamplona”) completed its acquisition of PAREXEL today. Pamplona acquired all outstanding shares of PAREXEL for $88.10 per share in cash. The transaction was approved overwhelmingly by stockholders on September 15, with more than 98% of votes cast in favor. PAREXEL stock will stop trading at the close of business today. Josef von R...
BOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL) ("PAREXEL" or the "Company"), a leading global biopharmaceutical services company, announced today that its shareholders, at a special meeting held on September 15, 2017 in Boston, Massachusetts, approved the previously announced proposed acquisition of the Company by certain investment funds affiliated with Pamplona Capital Management ("Pamplona"). 78.3 percent of the Company’s shares outstanding were voted, with more than 98 percent of the votes cast in favor...
BOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has launched a new end-to-end service offering to provide real-world data insights that help life science companies more effectively demonstrate product value. “In an increasingly competitive market, leveraging data to demonstrate value is critical. However, unstructured data can make it difficult to overcome gaps in real-world evidence,” said Joshua Schultz, Senior Vice ...
CORPORATES ISSUER IN-DEPTH 31 August 2017 Source Documents: Final OM (10 Aug 2017) Peer Group: Services See Snapshot User’s Guide  for terminology, analytical criteria and our ranking of covenant structures. This report contains Moody’s analysis of the principal protections and weaknesses of the covenant package of the Notes based on information contained in the Final OM dated 10 August
Parexel released fiscal fourth-quarter results, revealing top-line growth slightly higher than expectations, which was offset by charges related to the upcoming buyout of the company by Pamplona Capital Management. Organic revenue declined 2%, which was an upside considering we had more bearish expectations for Parexel’s clinical research business. After the June announcement of Pamplona’s planned all-stock acquisition of Parexel, we raised our fair value estimate to the $88.10 offer price. ...
BOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL) ("PAREXEL" or the "Company"), a leading global biopharmaceutical services company, today reported financial results for the fourth quarter and Fiscal Year 2017, which ended on June 30, 2017. “PAREXEL's revenue performance in the fourth quarter of Fiscal Year 2017 exceeded our expectations,” said Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL. “Revenue in the quarter increased 3.8% year over year, driven by growth in demand for ou...
BOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL) will release financial results for the Fourth Quarter and Fiscal Year 2017 on Monday, August 28, 2017, after the close of the stock market. PAREXEL will not host a conference call. About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to th...
BOSTON & OSAKA, Japan--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer Institute today announced that they have formed an alliance to advance clinical development in Japan. The partnership will aim to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and hematology, accelerating the development of innovative and effective new cancer treatments for patients. “Oncology continues to ...
CORPORATES CREDIT OPINION 8 August 2017 New Issue RATINGS PAREXEL International Corporation Domicile Massachusetts, United States Long Term Rating B2 Type LT Corporate Family Ratings Outlook Stable Please see the ratings section  at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Peter H. Abdill, CFA 212
Rating Action: Moody's assigns a B2 CFR to PAREXEL; outlook stable. Global Credit Research- 08 Aug 2017. New York, August 08, 2017-- Moody's Investors Service, assigned a B2 Corporate Family Rating and B2-PD Probability of Default Rating to PAREXEL International Corporation.
BOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (the “Company” or “PAREXEL”) (NASDAQ:PRXL) today announced that West Street Merger Sub, Inc. (“Merger Sub”), an affiliate of Pamplona Capital Management (the “Investor”), formed in connection with the previously announced proposed acquisition of the Company by certain investment funds affiliated with the Investor pursuant to the Agreement and Plan of Merger, dated as of June 19, 2017 (the “Merger Agreement”), by and among the Company, West Street Parent, LLC, a Delaware limit...
BOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Sy Pretorius, M.D., Senior Vice President and Chief Scientific Officer, and Evan Demestihas, M.D., RPh, Vice President, Worldwide Head of The Medical Affairs Company (TMAC), have been named to PharmaVOICE magazine’s list of the 100 most inspiring people in the life sciences industry. The honor, published in the July/August 2017 issue of PharmaVOICE, recognizes both leaders for their val...
BOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the CEO Roundtable on Cancer has again named PAREXEL a CEO Cancer Gold Standard™ employer. The biennial U.S.-based accreditation, which PAREXEL previously received in 2015, recognizes the Company’s strong commitment to the health of its employees and their families. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170711005056/en/...
BOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that for the second year in a row, Forbes has named the Company to its America’s “Best Employers” list. The list recognizes the top 300 midsized employers and top 500 large employers. Results are based on anonymous survey responses from 30,000 U.S. employees, with the most weighted factor being how likely they were to recommend their organizations to others. “Receiving th...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong are investigating the Board of Directors of PAREXEL International Corporation (NASDAQ:PRXL) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pamplona Capital Management, LLP. Under the terms of the deal, PAREXEL shareholders will receive $88.10 per share. The investigation concerns whether the PAREXEL Board of Directors breached their fiduciary duties to PAREXEL stockholders by failing to adequate...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of PAREXEL International Corporation (NASDAQ:PRXL) (“PAREXEL” or the “Company”) relating to the proposed buyout of PAREXEL by Pamplona Capital Management, LLP. Under the terms of the agreement, PAREXEL shareholders are anticipated to receive $88.10 in cash for each share of PAREXEL co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.